Aprogen/Nichi-Iko's Remicade Biosimilar Clears Japan’s Approval Review
Executive Summary
South Korea's Aprogen, which has teamed up with Japan's Nichi-Iko, is set to receive an official regulatory approval for its biosimilar infliximab in Japan and launch the product possibly this year, becoming the second Remicade biosimilar to be marketed in the country after Celltrion's Remsima.